Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., . . . Haass, C. (2016). sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med.
Citación estilo ChicagoSuárez‐Calvet, Marc, et al. "STREM2 Cerebrospinal Fluid Levels Are a Potential Biomarker for Microglia Activity in Early‐stage Alzheimer's Disease and Associate With Neuronal Injury Markers." EMBO Mol Med 2016.
Cita MLASuárez‐Calvet, Marc, et al. "STREM2 Cerebrospinal Fluid Levels Are a Potential Biomarker for Microglia Activity in Early‐stage Alzheimer's Disease and Associate With Neuronal Injury Markers." EMBO Mol Med 2016.